Pharmaceuticals

This section represents the official information about the pharmaceutical products registered at the Ministry of Public Health

Drugs registration follows a chain of links that are all submitted to the control of a Drug Registration Technical Committee (TC) at the MOPH. All pharmaceutical products must be registered at the MOPH whether being manufactured locally or imported. Any importation or distribution of drugs that is not submitted to the control of the MOPH is considered illegal and therefore is subject to confiscation.

Pharmaceutical Products Recalled from the Lebanese Market according to Minister's Decisions.

According to the French National Agency for Medicines and Health Products Safety (ANSM), Over-the-counter (OTC) drugs are medicines that are accessible to patients in pharmacies, based on criteria set to safeguard patients’ safety.
FDA’s Center for Drug Evaluation and Research (CDER) regulates over-the-counter (OTC) which are drugs that have been found to be safe and appropriate for use without the supervision of a health care professional such as a physician, and they can be purchased by consumers without a prescription.
Due to their therapeutic class, these medicines could be dispensed without physician’s intervention for diagnostic, treatment initiation or maintenance purposes.
According to Article 43 of the Law No.367 issued in 1994 related to the pharmacy practice, and the amendment of Articles 46 and 47 by Law No.91 issued in 2010, pharmacists do not have the right to dispense any medicine that is not requested through a unified prescription, unless the medicine is mentioned in a list which is established by the Orders of Pharmacists and Physicians...

According to the Law No. 91 issued on 2010 related to the Pharmacist substitution right, the Ministry of Public Health conceived the Substitution Drug list. It is presented as a scientific, objective, reliable, accurate and accessible listing. This list is a helpful tool for Pharmacists and Health professionals and an information tool for patients as well

Based on the current version of the WHO Model List of Essential medicines 20th edition published in 2017, the Ministry of Public Health in Lebanon through the Quality Assurance of Pharmaceutical Products Program prepared the National List of Essential Medicines EML 2018, four years after the last edition in 2014. The EML 2018 contains around 350 medicinal products and was prepared over one year by a Committee of Experts...

Upon the request of the Minister of Health, the UNDP TOKTEN project is launching the National Cancer Treatment Guidelines (second edition) based on the latest scientific updates. The first edition of the National Cancer Treatment Guidelines in 2010 had a very positive outcome that resulted in the provision of international standards of care for cancer patients subsidized by the Ministry of Health, Similarly to the first edition, an official national committee including 7 prominent Lebanese oncologists from different backgrounds resumed work on the guidelines supported by the TOKTEN project manager Mrs. Ariane Elmas Saikali. The outputs of the committee were transmitted to Lebanese expatriate oncologists from distinguished international cancer centers to be reviewed, discussed and approved. We are thankful to a Lebanese Expatriate, Mr. Monzer Hourani, who funded the publication of this booklet.

This section has been developed for individuals and organizations involved in health-related research with human participants. In particular, this document is intended to provide guidance to design and carry out health research studies to provide guidance on the requirements of the Lebanese Ministry of Public Health to approve a clinical trial in Lebanon.

Ethics is defined as what is right or wrong, good or bad; it varies from one person to another, and even between countries with culture playing an important role in the acceptance of ethical standards. Within this page, ethics governing the pharmaceutical profession is mentioned, in addition to the ethical standards to abide by throughout the process of drug promotion to ensure transparency between the parties involved. The page also defines conflicts of interest and includes the decree issued by the MOPH about this topic.